Theta Burst Stimulation in Pharmacologically Untreated Patients as Sole Antidepressant Treatment

NCT ID: NCT05732298

Last Updated: 2025-12-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-27

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, controlled trial in which 72 patients with depressive disorder were treated in two study arms using the non-invasive brain stimulation method of intermittent thetaburst intermittent theta burst stimulation (iTBS).

This is a wait-list control study, and the arms differ in the start of the four-week treatment (either promptly i.e., at the beginning of the next week of work) or delayed (start of treatment in four weeks).

The patients to be treated are those who refuse treatment with antidepressant medications.

The effectiveness of the four-week iTBS treatment is to be evaluated in comparison to a "watchful waiting" after 4 weeks.

A interim analysis is planned after 36 patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

active treatment

intermittent theta burst stimulation

Group Type EXPERIMENTAL

intermittend theta burst stimulation (iTBS)

Intervention Type DEVICE

600 pulses of iTBS per day with 120% resting motor threshold applied four weeks at Monday-Friday

waiting list

patients waiting for intervention

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intermittend theta burst stimulation (iTBS)

600 pulses of iTBS per day with 120% resting motor threshold applied four weeks at Monday-Friday

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

repetitive transcranial magnetic stimulation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* uni- or bipolar depression according to ICD-10
* present episode at least four weeks
* 18-70 years old
* no intake and rejection of anti-depressant medication and
* no adequate anti-depressant medication in the present episode
* no or stable non-drug anti-depressant treatment (e.g. psychotherapy)
* residency in Germany, German speaking

Exclusion Criteria

* contraindications for transcranial magnetic stimulation (electric devices or metal parts in the body such as pacemaker
* relevant neurological or internistic diseases according to study investigator
* participation in other trials during treatment
* pregnancy or breatfeeding
* legal care and placement in a psychiatric hospital
* active suicidality
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Regensburg

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Berthold Langguth, MD, Ph.D.

Prof. Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Berthold Langguth, Prof.

Role: PRINCIPAL_INVESTIGATOR

University Hospital of Regensburg, Department of Psychiatry and Psychotherapy at the Bezirksklinikum

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Psychiatry and Psychotherapy

Regensburg, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

22-3053-101

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Rapid Acting Transcranial Magnetic Stimulation
NCT04739969 ACTIVE_NOT_RECRUITING NA